Tumour hypoxia represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour regression. Tumour hypoxia can be detected by non-invasive techniques but the inter-relationship between these techniques needs to be better defined. [18F]Fluoromisonidazole (18F-MISO) and Cu-labelled diacetyl-bis(N (4)-methylthiosemicarbazone (Cu-ATSM) PET, and blood oxygen level-dependent (BOLD) MRI are the lead contenders for human application based on their non-invasive nature, ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate heterogeneity and general availability; these techniques are the primary focus of this editorial.

Author

Anwar R Padhani

Contact Details

Corresponding address:
Dr Anwar Padhani FRCP FRCR,
Consultant Radiologist and Head of Imaging Research,
Paul Strickland Scanner Centre,
Mount Vernon Hospital,
Rickmansworth Road,
Northwood, Middlesex, HA6 2RN, UK.

Reference

ICIS Cancer Imaging Volume 5 Issue 1
DOI: 10.1102/1470-7330.2005.0103

Date Posted

28 November 2005

Screen PDF

Size

144.98 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	2 seconds
64 Kb/s (ISDN):	18 seconds
33.3 Kb/s (Typical Modem):	34 seconds

Print PDF

Size

197.68 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	3 seconds
64 Kb/s (ISDN):	24 seconds
33.3 Kb/s (Typical Modem):	47 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.